ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CCND1	595	8826947	-	-	-	-	58	74	-	-	Shinshu University Hospital	I (n=51); II (n=8); III (n=15)	1 (n=39); 2 (n=23); 3 (n=12)	[1] The coabnormal expression of cyclin D1 and p53 protein may contribute to the development of endometrial carcinoma and may also be involved in the progression to malignancy. [2] The expression of cyclin D1 was restricted to only a few cells of normal and hyperplastic endometrium; whereas it was preferentially expressed in 40% (30/74) of endometrial carcinomas. The cells that overexpressed cyclin D1 also overexpressed p53. Moreover; all 30 cases with varied distributions of cyclin D1-positive cells corresponded identically with the distribution of p53-positive cells. Diffuse positivity for cyclin D1 was specifically observed in clinically advanced stages of pathologic G2 and G3 tumors. [2] The total cyclin D1 positive rate was 33.3% in stage I; 37.5% in stage II and 66.7% in stage III. Statistically; the cyclin D1 positive aret was significantly greater in stage III patients (p<0.05).	Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas	Cancer	78(6):1248-53	1996
CCND1	595	11900573	Endometrioid adenocarcinoma + Complex hyperplasia	Up regulation/ Over expression/High expression	-	-	13 proliferative; 11 secretory; 26 simple hyperplasia; 21 complex hyperplasia	37 endometrioid adenocarcinoma	-	-	Department of Pathology of Women and Infants Hospital; RI and Truman Medical Center; Kanas City; Mo.	-	-	[1] Overexpression of cyclin D1 increases from normal endometrium to hyperplasia and carcinoma; suggesting that it may play a role in endometrial carcinogenesis. Overexpression of cyclin D1 in endometrial glands was independent from overexpression of cyclin D1 in surface metaplastic epithelium. [2] Cyclin D1 was significantly overexpressed in glands with complex hyperplasia and endometrioid adenocarcinoma compared with proliferative or secretory endometrium and simple hyperplasia. Significant overexpression was also noted in papillary; syncytial; and squamous metaplasias compared with normal surface epithelium or epithelium with tubal metaplasia.	Expression of cyclin D1 in normal; metaplastic; hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis	Archives of Pathology and Laboratory Medicine	126(4):459-63	2002
CCND1	595	12955092	-	Mutation	-	-	-	60	31 to 89	62.47	Pathology Department of La Paz Hospital; Madrid	I (n=45); II (n=7); III/IV (n=7)	1 (n=29); 2 (n=20); 3 (n=11)	[1] CCND1 mutations affecting critical residues involved in protein degradation. [2] There was a statistically significant relationship between cyclin D1 expression and tumor grade (P=0.03); whereby cyclin D1 overexpression (cyclin D1 expression in more than 25% of neoplastic cells) was observed in 36.3% of grade 3 carcinomas; but only in 13 and 5% of grade 1 and 2 carcinomas; respectively. [3] It was found that two EECs with cyclin D1 expression in more than 50% of the cells had single-base substitutions affecting codon 287; one CCC to ACC and one CCC to TCC change leading to a change from proline to threonine and serine; respectively	Cyclin D1 gene (CCND1) mutations in endometrial cancer	Oncogene	22(38):6115-8	2003
CCND1	595	14740230	Proliferative Endometrium (30); Hyperplasia (29); Endometrium Carcinoma (30)	Up regulation/ Over expression/High expression	-	-	-	30 (Proliferative Endometrium); 14 (Atypical Endometrial Hyperplasia; 15 (Simple Endometrial Hyperplasia); 30 ( Endometrium Carcinoma).	47 to 75	59.3	-	I (n=21); II (n=3); III (n=6)	1 (n=20);2 (n=6); 3 (n=4)	[1] One out of 30 patients (3.3%) with proliferative endometrium; 1 out of 14 patients (7.1%) with atypical hyperplasia; and 8 out of 30 patients (26.6%) with endometrial carcinoma were found to have immunoreactivity to cyclin D1. [2] Cyclin D1 expression in endometrial carcinoma is higher than proliferative endometrium and simple hyperplasia. These findings support that cyclin D1 may play a role in endometrial carcinogenesis.	Expression of cyclin D1 in normal; hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables	Archives of Gynecology and Obstetrics	271(2):123-6	2005
CCND1	595	15863141	Endometrial adenocarcinoma	Polymorphism	-	-	154	77	-	-	Seoul National University Hospital; South Korea	-	-	[1] CCND1 G870A polymorphism is associated with an increased risk of endometrial cancer. [2] Conditional logistic regression adjusted for various risk factors of endometrial cancer revealed positive associations between the AA genotype and an increased risk of endometrial cancer (OR 3.16; 95% CI 1.18-8.43; P = 0.022). [3] The OR of the AA genotype is 2.14 (95% CI= 1.02 to 4.48; P=0.044) which supports the recessive nature of A allele. [4] The CCND1-Rb-p16 pathway has been suggested to be associated with endometrial carcinoma.	Cyclin D1 polymorphism and the risk of endometrial cancer.	Gynecologic Oncology	97(2):431-5	2005
CCND1	595	18822177	-	Polymorphism	-	-	291	191	-	-	Hunter Centre for Gynaecological Cancer; John Hunter Hospital; NewCastle; New South Wales; Australia	-	-	[1] The cyclin D1 870 G>A polymorphism is possibly involved in the development of endometrial cancer.Women homozygous for the variant cyclin D1 870 AA genotype showed a trend for an increased risk of developing endometrial cancer compared to those with the wild-type GG genotype. [2] There is a trend for increased risk of developing endometrial cancer for women with the AA genotype compared to those with the GG genotype (ORadj 1.692 95% CI (0.939–3.049); p = 0.080).	The influence of the Cyclin D1 870 G>A polymorphism as an endometrial cancer risk factor.	BMC Cancer	0.522222222	2008
CCND1	595	19502783	Endometroid adenocarcinoma+ Serous papillary	-	-	-	-	126 (endometroid adenocarcinoma 83+ adenosquamous carcinoma 16+ serous papillary 27+ adenocarcinoma 14+ clear cell carcinoma 11+ squamous cell carcinoma 2)	25 to 74	53.5	Qilu Hospital of Shandong University	"I (n=69)	II (n=10)	III (n=45)	IV (n=2)"	"1 (n=58)	2 (n=41)	3